moatshark My

All holdings

Guardant Health

GH

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$5.2m
Combined value at quarter end
Last quarter
0 bought
1 sold or trimmed
Price at Q2 ’26 end
$150.03
+62.4% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+20.1%Q3 ’25
+63.5%Q4 ’25
-9.6%Q1 ’26
+62.4%Q2 ’26
Q3 ’25: +20.1%; Q4 ’25: +63.5%; Q1 ’26: -9.6%; Q2 ’26: +62.4%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
0Q2 ’24
0Q3 ’24
0Q4 ’24
0Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 0; Q3 ’24: 0; Q4 ’24: 0; Q1 ’25: 0; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Guardant Health.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Guardant Health
Polen Capital Management0.0%$5.2m$5.2mTrimmed -1.0%5 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Guardant Health
Bought or soldFiling
16 Oct 2026Tariq MusaDirector▼ Sold116$165.88$19kForm 4
14 Oct 2026Azar Alex M IIDirector▼ Sold69$159.89$11kForm 4
16 Sep 2026Krognes Steve E.Director▼ Sold3,300$175.42$579kForm 4
16 Sep 2026Krognes Steve E.Director▼ Sold1,300$176.34$229kForm 4
16 Sep 2026Krognes Steve E.Director▼ Sold1,103$174.46$192kForm 4
16 Sep 2026Krognes Steve E.Director▼ Sold971$177.48$172kForm 4
16 Sep 2026Azar Alex M IIDirector▼ Sold826$175.00$145kForm 4
16 Sep 2026Tariq MusaDirector▼ Sold116$175.00$20kForm 4
15 Sep 2026Chudova DaryaChief Technology Officer▼ Sold7,738$178.00$1.4mForm 4
11 Sep 2026Kalia KumudChief Information Officer▼ Sold4,000$158.05$632kForm 4
21 Aug 2026Talasaz AmiraliCo-Chief Executive Officer▼ Sold20,888$169.16$3.5mForm 4
21 Aug 2026Talasaz AmiraliCo-Chief Executive Officer▼ Sold9,023$168.20$1.5mForm 4
21 Aug 2026Talasaz AmiraliCo-Chief Executive Officer▼ Sold7,589$170.29$1.3mForm 4
17 Aug 2026Tariq MusaDirector▼ Sold116$156.45$18kForm 4
12 Aug 2026Monroe Terilyn J.Chief People Officer▼ Sold19,014$165.16$3.1mForm 4
12 Aug 2026Monroe Terilyn J.Chief People Officer▼ Sold13,248$166.11$2.2mForm 4
12 Aug 2026Monroe Terilyn J.Chief People Officer▼ Sold9,934$164.27$1.6mForm 4
12 Aug 2026Monroe Terilyn J.Chief People Officer▼ Sold3,704$163.41$605kForm 4
12 Aug 2026Monroe Terilyn J.Chief People Officer▼ Sold400$167.92$67kForm 4
10 Aug 2026Freeman ChrisChief Commercial Officer▼ Sold35,364$169.63$6.0mForm 4

About the company

Sector
Health care · Services-Medical Laboratories
Incorporated in
Delaware
Financial year ends
31 December
Shares outstanding
134m at 24 Jul 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$25.2m2016
$49.8m2017
$90.6m2018
$214m2019
$287m2020
$374m2021
$450m2022
$564m2023
$739m2024
$982m2025
2016: $25.2m; 2017: $49.8m; 2018: $90.6m; 2019: $214m; 2020: $287m; 2021: $374m; 2022: $450m; 2023: $564m; 2024: $739m; 2025: $982m
Guardant Health revenue and net income by year
YearRevenueNet income
2025$982m−$416m
2024$739m−$436m
2023$564m−$479m
2022$450m−$655m
2021$374m−$385m
2020$287m–
2019$214m−$75.7m
2018$90.6m−$85.1m
2017$49.8m−$83.2m
2016$25.2m−$46.1m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.